Lorraine Leblond

Antivascular and antitumor evaluation of 2-amino-4-(3-bromo-4,5-dimethoxy-phenyl)-3-cyano-4<i>H</i>-chromenes, a novel series of anticancer agents

Henriette Gourdeau, Lorraine Leblond, Bettina A. Hamelin et al. · Molecular Cancer Therapeutics · 2004 · 289 citations

Medicine, Medicinal Chemistry, Pharmacology +14

Evaluation of Proteinase-Activated Receptor-1 (PAR1) Agonists and Antagonists Using a Cultured Cell Receptor Desensitization Assay: Activation of PAR2 by PAR1-Targeted Ligands

Atsufumi Kawabata, Mahmoud Saifeddine, Bahjat Al‐Ani et al. · Journal of Pharmacology and Experimental Therapeutics · 1999 · 211 citations

Life Sciences, Biochemistry, Pharmacology +15

A novel RGD antagonist that targets both αvβ3 and α5β1 induces apoptosis of angiogenic endothelial cells on type I collagen

Karen Meerovitch, Frédéric Bergeron, Lorraine Leblond et al. · Vascular Pharmacology · 2003 · 67 citations

Life Sciences, Cell Biology, Medicinal Chemistry +13

The amphipathic alpha-helical repeats of apolipoprotein A-I are responsible for binding of high density lipoproteins to HepG2 cells.

Lorraine Leblond, Yves L. Marcel · Journal of Biological Chemistry · 1991 · 56 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +12

BCH-2763, a Novel Potent Parenteral Thrombin Inhibitor, Is an Effective Antithrombotic Agent in Rodent Models of Arterial and Venous Thrombosis – Comparisons with Heparin, r-Hirudin, Hirulog, Inogatran and Argatroban

C D Finkle, Lorraine Leblond, Isabelle Deschênes et al. · Thrombosis and Haemostasis · 1998 · 43 citations

Medicine, Pharmacology, Pharmacotherapy +17